The FDA paused a policy that would proactively release drug rejection letters as the agency works to formalize the approach via rulemaking. The halt follows a citizen’s petition submitted by an unnamed pharma company in April, according to Fierce Biotech coverage. The policy is designed to clarify how and when the FDA’s rationale for rejection decisions is disclosed publicly. The delay underscores ongoing debate about transparency versus proprietary and compliance considerations tied to rejection communications. For biopharma teams, the change affects how regulatory feedback may be surfaced externally, with potential implications for how sponsors interpret patterns in rejection rationales during development and CMC planning.